Device bar coding
This article was originally published in The Gray Sheet
Executive Summary
FDA remains receptive to industry concerns about the logistics of requiring bar codes for devices, according to agency staff. Obstacles include product diversity and the lack of a unique identification system comparable to the National Drug Code (NDC). Views on the topic likely differ across FDA; CBER, for example, was not included in an April 13-14 FDA/industry meeting to consider device bar-coding and alternatives such as radiofrequency tags (1"The Gray Sheet" April 22, 2005, p. 6). FDA may decide on the matter shortly; in a FDL-1May 9 letter, hospital associations join group purchasing organization Premier in urging the agency to add devices to products for which bar coding is required under a February 2004 rule. The letter follows a similar one from Rep. Pete Sessions (R-Texas) to the agency. FDA staff registered surprise at the second letter, since most of the signatories were present at the April meeting...
You may also be interested in...
Reps urge mandatory device bar coding
"A compelling patient safety interest...lies in requiring bar codes for certain medical devices, including implantable items like hip/knee prosthetics, stents and CRM pacers, which could be subject to recalls," Rep. Pete Sessions (R-Tex.) states in FDL-1May 24 letter to FDA Acting Commissioner Lester Crawford. The letter is signed by six other representatives. Meanwhile, AdvaMed advises Crawford in a May 19 letter to keep bar coding voluntary for devices. Hospital groups recently issued a letter urging FDA to extend bar coding requirements to devices under a February 2004 rule (1"The Gray Sheet" May 16, 2005, In Brief)...
Bar Coding Advocacy Gathers Momentum? FDA, Rep. Sessions Scan Options
Rep. Pete Sessions (R-Texas) is urging FDA to explore a bar code requirement for medical devices
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.